海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

休市中 04-02 16:08:19

176.700

-3.400

-1.89%

最高180.700	最低165.000	成交量55.86万
今开180.100	昨收180.100	日振幅8.72%
总市值139.08亿	流通市值139.08亿	总股本7,871万
成交额9,701万	换手率0.71%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":176.7,"timestamp":1775117299648,"preClose":180.1,"halted":0,"volume":558550,"delay":0,"changeRate":-0.018878400888395368,"floatShares":78707270,"shares":78707270,"eps":2.9007179358560364,"marketStatus":"休市中","change":-3.4,"latestTime":"04-02 16:08:19","open":180.1,"high":180.7,"low":165,"amount":97011980,"amplitude":0.087174,"askPrice":176.7,"askSize":200,"bidPrice":176.4,"bidSize":50,"shortable":0,"etf":0,"ttmEps":2.8324657491300123,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":180.1,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.76037681908109,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637","defaultTab":"news","newsList":[{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","06855","02162","06978","BK1593","159992","01477","09969","02637","BK1574","HK0000165453.HKD","06955","02157","09995","BK1583","01530","BK1161","LU2328871848.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624568490","title":"港股异动 | 海西新药(02637)绩后涨超8% 25年度净利同比增超三成 海慧通新入选国家VBP计划规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624568490","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624568490?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:13","pubTimestamp":1775009626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药(02637)绩后涨超8%，截至发稿，涨8.06%，报172.9港元，成交额6217.15万港元。消息面上，3月31日，海西新药公布2025年业绩，收益为约5.82亿元，同比增长24.79%；净利约1.77亿元，同比增长30.09%；每股盈利为2.55元。公告称，收益增加主要归因于集团年内增强营销力度，带动海慧通®及安必力®的销售收入增长。特别是，海慧通®于2025年新入选国家VBP计划规格(5mg/20mg×14片)，有效推动医院渠道拓展及终端市场销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK1191","BK4588","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347378","title":"海西新药(02637)公布2025年业绩 净利约1.77亿元 同比增长30.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347378","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623347378?lang=zh_cn&edition=full","pubTime":"2026-03-31 00:17","pubTimestamp":1774887449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)公布2025年业绩，收益为约5.82亿元，同比增长24.79%;净利约1.77亿元，同比增长30.09%;每股盈利为2.55元。公告称，收益增加主要归因于集团年内增强营销力度，带动海慧通®及安必力®的销售收入增长。特别是，海慧通®于2025年新入选国家VBP计划规格(5mg/20mg×14片)，有效推动医院渠道拓展及终端市场销售增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)公布2025年业绩 净利约1.77亿元 同比增长30.09%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192657544","title":"海西新药2025年营收5.82亿元 同比增长逾两成","url":"https://stock-news.laohu8.com/highlight/detail?id=1192657544","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192657544?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:39","pubTimestamp":1774881583,"startTime":"0","endTime":"0","summary":"海西新药截至2025年12月31日止财政年度录得收益人民币5.82亿元，较2024年的4.67亿元上升24.79%。同期内，净利润为1.77亿元，较上年度的1.36亿元增长30.09%，每股盈利由人民币2.02元增加至人民币2.55元。公司指，收入主要来自14种已获批准药品销售，报告期内药品销售收入为5.81亿元，服务收入为130.30万元。至2025年年底，已动用约74.66百万元人民币款项，主要用于创新药临床试验及产品组合拓展、生产系统及商业化能力提升，以及一般营运资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043977","title":"港股异动 | 海西新药(02637)早盘涨超4% HXP056完成一期临床招募并启动二期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043977","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622043977?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:34","pubTimestamp":1774406097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药早盘涨超4%，截至发稿，涨3.42%，报148港元，成交额1946.04万港元。消息面上，海西新药发布公告，HXP056已于2025年7月初启动中国wAMD患者一期临床试验，目前已完成单次给药剂量递增与多次给药剂量递增阶段全部患者招募，并在连续给药四周后完成剂量限制性毒性评估及药代动力学数据收集；初步疗效评估同步进行中。2025年第四季度，公司已启动二期临床剂量扩展研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK4588","02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050170","title":"海西新药(02637)：wAMD口服药物项目HXP056完成一期临床研究招募并启动二期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050170","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050170?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:13","pubTimestamp":1774343638,"startTime":"0","endTime":"0","summary":"2025年第四季度，公司亦已启动剂量扩增的二期临床研究。HXP056有望成为全球首款治疗上述视网膜疾病的口服药物，这不仅代表重大技术突破，更蕴含爆发性的全球市场潜力。针对wAMD的HXP056一期临床研究初步数据显示，该药物具备良好安全性与耐受性，且呈现明确的剂量-暴露关系。基于这些令人鼓舞的初步成果，公司于2025年第四季度已经开始中国二期扩展研究的患者招募，而彼时一期剂量递增研究仍在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618426409","title":"海西新药创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618426409","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618426409?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:30","pubTimestamp":1773192654,"startTime":"0","endTime":"0","summary":"格隆汇3月11日丨海西新药(02637.HK)涨0.9%，报167.6000港元，股价创历史新高，总市值131.91亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093111a6b69dfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093111a6b69dfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618690919","title":"海西新药拟3月30日举行董事会会议审批全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618690919","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618690919?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:37","pubTimestamp":1773131851,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨海西新药(02637.HK)宣布，将于2026年3月30日（星期一）召开董事会会议，以审议及批准本集团截至2025年12月31日止年度的年度业绩以作刊发之用及处理其他事项，包括建议派付末期股息（如有）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603101637429546bda5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603101637429546bda5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618496904","title":"海西新药03月10日获主力加仓9.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618496904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618496904?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:15","pubTimestamp":1773130537,"startTime":"0","endTime":"0","summary":"03月10日, 海西新药股价涨19.32%，报收166.10元，成交金额8692.2万元，换手率0.72%，振幅20.11%，量比4.14。海西新药今日主力资金净流入9.2万元，上一交易日主力净流入250.6万元。该股近5个交易日上涨16.41%，主力资金累计净流入152.2万元；近20日主力资金累计净流入137.4万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161752a6b4c696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161752a6b4c696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618027996","title":"海西新药03月09日主力净流入250.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618027996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618027996?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:15","pubTimestamp":1773044131,"startTime":"0","endTime":"0","summary":"03月09日, 海西新药股价涨11.09%，报收139.20元，成交金额4884.2万元，换手率0.45%，振幅13.09%，量比4.68。海西新药今日主力资金净流入250.6万元，上一交易日主力净流出107.7万元。该股近5个交易日下跌4.36%，主力资金累计净流入101.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入128.2万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161716a45ad4c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161716a45ad4c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683999","title":"海西新药(02637)：刘国贤获委任为联席公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683999","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683999?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:38","pubTimestamp":1772786284,"startTime":"0","endTime":"0","summary":"张俊环女士(张女士)仍为其中一名联席公司秘书。刘国贤先生(刘先生)已获委任为联席公司秘书、授权代表及法律程序代理人，自2026年3月6日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617659895","title":"海西新药03月06日主力净流出107.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2617659895","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617659895?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784933,"startTime":"0","endTime":"0","summary":"03月06日, 海西新药股价跌9.47%，报收125.30元，成交金额1592.1万元，换手率0.15%，振幅10.40%，量比1.77。海西新药今日主力资金净流出107.7万元，上一交易日主力净流入0.1万元。该股近5个交易日下跌14.34%，主力资金累计净流出142.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出137.1万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161726a6aa2b30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161726a6aa2b30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142351494","title":"海西新药（02637）2月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1142351494","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142351494?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:42","pubTimestamp":1772700123,"startTime":"0","endTime":"0","summary":"海西新药（02637）于2026年3月5日披露了截至2026年2月28日的股份变动月报表。根据公告，福建海西新药创制股份有限公司在报告期内法定注册股本总额为人民币78,707,270元，普通股H股已发行总数维持在78,707,270股，面值每股人民币1元，较上月底无任何增减变化。\n公告显示，当月没有新增发行、购回、注销或库藏股活动，也无任何股份期权、权证及可换股票据等相关变动。截至2月底，公司已发行股本与上月相比保持相同数量，股本结构稳定。该公告由公司联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337961","title":"正大天晴骨髓纤维化双靶点新药上市；海西新药任命张明强为研发总裁；默沙东启动首创眼科双抗II/III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337961","media":"药财社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616337961?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:59","pubTimestamp":1772449183,"startTime":"0","endTime":"0","summary":"此次获批标志着国内骨髓纤维化一线治疗正式步入双靶点时代，有望填补中晚期患者沉重的临床需求空白。2海西新药任命张明强为研发总裁福建海西新药于2026年3月1日发布官方公告，正式任命张明强博士出任集团研发与全球事务总裁。3默沙东启动首创眼科双抗II/III期研究近日，美国临床试验收录网站显示，默沙东正式启动其全球首创眼科双抗药物tiespectus的首个II/III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302203357a4423134&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302203357a4423134&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337627","title":"药企上市4个月，挖来外企65岁高管","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337627","media":"医药之梯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616337627?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:38","pubTimestamp":1772444304,"startTime":"0","endTime":"0","summary":"3月1日， 海西新药 发布公告宣布，张明强博士已获委任为本集团研发与全球事务总裁，自2026年3月1日起生效。张明强博士，65岁，在制药及生物科技行业拥有丰富经验。2025年10月20日，海西新药正式登陆港交所。招股书显示，2022年至2024年，海西新药营收从2.12亿元增长至4.67亿元，净利润从6898万元增长至1.36亿元。2025年前五个月，海西新药实现营收2.49亿元，净利润9021万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302175402a441a7d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302175402a441a7d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616982103","title":"海西新药任命张明强为研发与全球事务总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2616982103","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616982103?lang=zh_cn&edition=full","pubTime":"2026-03-01 18:40","pubTimestamp":1772361646,"startTime":"0","endTime":"0","summary":"海西新药（02637）发布公告，董事会宣布，张明强博士自2026年3月1日起被任命为本集团研发与全球事务总裁。张博士在制药及生物科技行业拥有丰富经验，曾在多个国际知名公司担任重要职务，包括英国格拉斯哥Organon研究实验室、BioticaTechnologyLtd、罗氏制药中国研发中心及AmgenInc.等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603013657731012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611100938","title":"海西新药02月16日获主力加仓23.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611100938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611100938?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:15","pubTimestamp":1771229749,"startTime":"0","endTime":"0","summary":"02月16日, 海西新药股价涨1.61%，报收138.70元，成交金额1345.9万元，换手率0.12%，振幅2.34%，量比1.71。海西新药今日主力资金净流入23.0万元，上一交易日主力净流入5.3万元。该股近5个交易日下跌1.56%，主力资金累计净流入28.3万元；近20日主力资金累计净流入242.1万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161851a4a9ee5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161851a4a9ee5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124936191","title":"福建海西(2637)宣布认购基金挂钩票据与China Rock Fund 涉资最多4亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124936191","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124936191?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:41","pubTimestamp":1770280913,"startTime":"0","endTime":"0","summary":"香港主板上市公司福建海西新药创制股份有限公司董事会公告，于2025年10月24日动用闲置资金分别认购由Essence Global Investment Limited发行的基金挂钩票据，认购本金2亿港元，以及最多2亿港元的China Rock Fund SPC。该两项认购构成须予披露交易，最高适用百分比率超过5%但低于25%，需遵守香港上市规则第14章中的通知及公告规定。China Rock Fund SPC为保本产品，预期年化回报率2.5%至6.0%，投资范围包括短期优质货币市场工具与现金等价物，允许随时赎回。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609223283","title":"海西新药(02637)认购金融产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2609223283","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609223283?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:37","pubTimestamp":1770280650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，于2025年10月24日，福建海西新药创制股份有限公司(本公司)作为投资者，动用其闲置资金，认购2亿港元由Essence Global Investment Limited根据其10亿美元有担保结构性票据计划发行的2025-32系列基金挂钩票据;及最多2亿港元的China Rock Fund SPC。合理有效地利用临时闲置资金可提高本公司的资本收益，与本公司确保资金安全和流动性以及满足本集团日常运营及股息派付的资金需求这一核心目标一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","159940","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124721723","title":"福建海西新药创制（02637）1月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1124721723","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124721723?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:37","pubTimestamp":1770280629,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司（股份代号：02637）于2026年2月5日公布2026年1月股份变动月报，报告期为2026年1月1日至1月31日。\n截至本月末，公司法定股本为人民币78,707,270元，普通股H股已发行股份总数维持在78,707,270股，无库存股份。报告期内未进行任何新增发行、购回或注销股份，股本结构保持稳定。\n公司同时确认已符合香港联交所对公众持股量的相关要求。公告由公司联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.2086},{"period":"1month","weight":0.2186},{"period":"3month","weight":0.3397},{"period":"6month","weight":1.0451},{"period":"ytd","weight":0.2993}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}